ApprovalTrail

Drug · DIN 02423049

REVOLADE

No: cancelled before it was sold

Authorized, then cancelled before it was ever sold in Canada.

Status Cancelled Pre Market since March 11, 2020.
Drug Identification Number (DIN)
02423049
Company (DIN owner)
Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
Schedule
Prescription
Dosage form
Tablet
Route
Oral
Therapeutic class (ATC)
Eltrombopag B02BX05
Class
Human
Record last updated
March 22, 2025

Active ingredients

As listed in the Drug Product Database.

IngredientStrengthPer
ELTROMBOPAG (ELTROMBOPAG OLAMINE)75 MG

Notices of Compliance

Health Canada approvals that name this DIN.

  • July 30, 2015: NOC 17147New Drug Submission (NDS) · Transfer of Drug Identification Number(s)
  • March 27, 2014: NOC 15516Supplement to a New Drug Submission (SNDS) · Addition of new strength - 75 mg tablet. addition of new indication; to increase platelet counts in thrombocytopenic patients with chronic hepatgitis C virus (hcv)

Other DINs named REVOLADE